{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:31:13Z","timestamp":1780489873684,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s12325-023-02484-3","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T10:02:17Z","timestamp":1683021737000},"page":"2836-2854","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cost-Effectiveness of Pembrolizumab as an Adjuvant Treatment in Colombia for Melanoma Patients with Lymph Node Involvement After Complete Resection"],"prefix":"10.1007","volume":"40","author":[{"given":"Cesar","family":"Lopez-Vinueza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Urrego-Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredy R. S.","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Wurcel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Zambrano Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Dhankhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baanie","family":"Sawhney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gargi","family":"Baluni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrishti","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debosmita","family":"Bhadra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,2]]},"reference":[{"key":"2484_CR1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/nature05661","volume":"445","author":"V Gray-Schopfer","year":"2007","unstructured":"Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature. 2007;445:851\u20137.","journal-title":"Nature"},{"key":"2484_CR2","first-page":"14","volume":"1017","author":"D Loria","year":"2020","unstructured":"Loria D, Abriata M, Santoro F, Latorre C. Cutaneous melanoma in Argentina: an analysis of its characteristics and regional differences. eCancer Med Sci. 2020;1017:14.","journal-title":"eCancer Med Sci."},{"key":"2484_CR3","unstructured":"Global Cancer Observatory. Globocan 2020, World factsheet. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/900-world-fact-sheets.pdf."},{"issue":"1","key":"2484_CR4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/bjd.15510","volume":"177","author":"C Karimkhani","year":"2017","unstructured":"Karimkhani C, Green A, Nijsten T, et al. The global burden of melanoma: Results from the Global Burden of Disease Study 2015. Br J Dermatol. 2017;177(1):134\u201340.","journal-title":"Br J Dermatol"},{"key":"2484_CR5","unstructured":"Global Cancer Observatory. Globocan 2020, Colombia Factsheet. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/170-colombia-fact-sheets.pdf."},{"key":"2484_CR6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ejca.2016.05.005","volume":"63","author":"C Garbe","year":"2016","unstructured":"Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline\u2014Update 2016. Eur J Cancer. 2016;63:201\u201317.","journal-title":"Eur J Cancer"},{"key":"2484_CR7","unstructured":"National Comprehensive Cancer Network (NCCN) Melanoma. NCCN clinical practice guidelines in oncology. Version 2. 2018. https:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/melanoma.pdf."},{"key":"2484_CR8","unstructured":"Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group: Clinical study reportEORTC protocol 1325-MG\/KEYNOTE-054. https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT02362594."},{"key":"2484_CR9","unstructured":"Opdivo (nivolumab): Highlights of Prescribing Information. Initial U.S. Approval: Bristol-Myers Squibb Company. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125554s099lbl.pdf."},{"key":"2484_CR10","unstructured":"Yervoy (ipilimumab): Highlights of Prescribing Information. Initial U.S. Approval: Bristol-Myers Squibb Company. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125377s115lbl.pdf."},{"key":"2484_CR11","unstructured":"Keytruda: EPAR\u2014Product Information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/keytruda-epar-product-information_en.pdf."},{"key":"2484_CR12","unstructured":"Keytruda (pembrolizumab): Highlights of Prescribing Information. Initial U.S. Approval: Merck Sharp & Dohme Corp. 2014. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125514s105lbl.pdf."},{"key":"2484_CR13","unstructured":"Cotellic (cobimetinib): Highlights of Prescribing Information. Initial U.S. Approval: Genentech. 2015. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/206192s002lbl.pdf."},{"key":"2484_CR14","unstructured":"Zelboraf (vemurafenib): Highlights of Prescribing Information. Initial U.S. Approval: Genentech. 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/202429s009lbl.pdf."},{"key":"2484_CR15","unstructured":"Mekinist (Trametinib): Highlights of Prescribing Information. Initial U.S. Approval: Novartis. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/204114s007lbl.pdf."},{"key":"2484_CR16","unstructured":"Tafinlar (Dabrafenib): Highlights of Prescribing Information. Initial U.S. Approval: Novartis. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/202806s008lbl.pdf."},{"key":"2484_CR17","unstructured":"National Institute for Food and Drug Surveillance (INVIMA). Product Data. https:\/\/consultaregistro.invima.gov.co\/Consultas\/consultas\/consreg_encabcum.jsp."},{"issue":"5","key":"2484_CR18","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","volume":"22","author":"A Eggermont","year":"2021","unstructured":"Eggermont A, Blank C, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): Distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(5):643\u201354.","journal-title":"Lancet Oncol"},{"key":"2484_CR19","unstructured":"Ministry of Health and Social Protection (Minsalud). National Survey of the Nutritional Situation in Colombia (ENSIN). 2015. https:\/\/www.minsalud.gov.co\/sites\/rid\/Lists\/BibliotecaDigital\/RIDE\/VS\/ED\/GCFI\/libro-ensin-2015.pdf."},{"key":"2484_CR20","unstructured":"Institute for Health Technology Assessment (IETS). Handbook Methodological for Assessment of Heath Techonologies. https:\/\/www.iets.org.co\/."},{"key":"2484_CR21","unstructured":"Bank of The Republic\u2014Colombia. Consumer Price Index. 2021. https:\/\/www.banrep.gov.co\/es\/estadisticas\/indice-precios-consumidor-ipc."},{"key":"2484_CR22","unstructured":"World Health Organisation (WHO). Guide to Cost-effectiveness Analysis. 2003. http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/42699\/9241546018.pdf?sequence=1."},{"key":"2484_CR23","unstructured":"National Administrative Department of Statistics (DANE). Quarterly National Gross Domestic Product\u2014GDP. Main Results for Fourth Quarter of 2021. 2022 February 15. https:\/\/www.dane.gov.co\/files\/investigaciones\/boletines\/pib\/presen_rueda_de_prensa_PIB_IVtrim21.pdf."},{"issue":"10105","key":"2484_CR24","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter J, Ribas A, Long G, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853\u201362.","journal-title":"Lancet"},{"issue":"4","key":"2484_CR25","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/0272989X16651869","volume":"37","author":"C Williams","year":"2017","unstructured":"Williams C, Lewsey J, Briggs A, Mackay D. Cost-effectiveness analysis in R using a multi-state modeling survival analysis framework: a tutorial. Med Decis Making. 2017;37(4):340\u201352.","journal-title":"Med Decis Making"},{"issue":"4","key":"2484_CR26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1177\/0272989X16670617","volume":"37","author":"C Williams","year":"2017","unstructured":"Williams C, Lewsey J, Mackay D, Briggs A. Estimation of survival probabilities for use in cost-effectiveness analyses: a comparison of a multi-state modeling survival analysis approach with partitioned survival and markov decision-analytic modeling. Med Decis Making. 2017;37(4):427\u201339.","journal-title":"Med Decis Making"},{"key":"2484_CR27","unstructured":"National Institute for Health and Care Excellence. DSU Technical Support Document 19: Partitioned survival analysis for decision modelling in health care: a critical review. 2017 June 2. http:\/\/nicedsu.org.uk\/technical-support-documents\/partitioned-survival-analysis-tsd\/."},{"key":"2484_CR28","unstructured":"United Nations (UN). Department of Economic and Social Affairs Population Division. World Population Prospects. 2022. https:\/\/population.un.org\/wpp\/Download\/Standard\/Mortality\/."},{"key":"2484_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-13-13","volume":"13","author":"S Hinchliffe","year":"2013","unstructured":"Hinchliffe S, Lambert P. Flexible parametric modelling of cause-specific hazards to estimate cumulative incidence functions. BMC Med Res Methodol. 2013;13:13.","journal-title":"BMC Med Res Methodol"},{"key":"2484_CR30","unstructured":"Flatiron Health Database2018. http:\/\/www.flatiron.com\/real-world-evidence."},{"issue":"4","key":"2484_CR31","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1524-4733.2008.00468.x","volume":"12","author":"F Augustovski","year":"2009","unstructured":"Augustovski F, Irazola V, Velazquez A, Gibbons L, Craig B. Argentine valuation of the EQ-5D health states. Value Health. 2009;12(4):587\u201396.","journal-title":"Value Health"},{"issue":"3","key":"2484_CR32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/sj.bjc.6605187","volume":"101","author":"K Beusterien","year":"2009","unstructured":"Beusterien K, Szabo S, Kotapati S, et al. Societal preference values for advanced melanoma health states in the United Kingdom and Australia. Br J Cancer. 2009;101(3):387\u20139.","journal-title":"Br J Cancer"},{"key":"2484_CR33","unstructured":"Drug and Medical Device Price Information System (SISMED). Drug Cost Database2021. https:\/\/web.sispro.gov.co\/WebPublico\/Consultas\/ConsultarCNPMCadenaComercializacionCircu2yPA_028_2_2.aspx."},{"key":"2484_CR34","unstructured":"Ministry of Health and Social Protection of Colombia (Minsalud). Medicines regulation prices. 2021. https:\/\/www.minsalud.gov.co\/salud\/MT\/Paginas\/medicamentos-regulacion-precios.aspx."},{"key":"2484_CR35","unstructured":"Social Security Institute (ISS). Tariff Manual. 2001. https:\/\/lexsaludcolombia.files.wordpress.com\/2010\/10\/tarifas-iss-2001.pdf."},{"key":"2484_CR36","unstructured":"National Institute for Health and Care Excellence (NICE). Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma [TA319]. 2014."},{"key":"2484_CR37","unstructured":"National Institute for Health and Care Excellence. NICE Pathway: Melanoma. https:\/\/pathways.nice.org.uk\/pathways\/melanoma#path=view%3A\/pathways\/melanoma\/managing-melanoma.xml&content=view-index."},{"key":"2484_CR38","unstructured":"Federation of Colombian Insurers (SOAT). Tariff Manual. https:\/\/fasecolda.com\/cms\/wp-content\/uploads\/2021\/01\/Manual-tarifario-2021.pdf."},{"issue":"1","key":"2484_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.rccan.2018.01.002","volume":"22","author":"S Prada","year":"2018","unstructured":"Prada S, Contreras J. Last-year-of-life expenditure of patients diagnosed with cancer. Colomb J Cancerol. 2018;22(1):3\u20137.","journal-title":"Colomb J Cancerol"},{"issue":"10","key":"2484_CR40","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/13696998.2019.1609485","volume":"22","author":"A Bensimon","year":"2019","unstructured":"Bensimon A, Zhou Z, Jenkins M, et al. Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States. J Med Econ. 2019;22(10):981\u201393.","journal-title":"J Med Econ"},{"issue":"1","key":"2484_CR41","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s40487-021-00142-8","volume":"9","author":"V Wurcel","year":"2021","unstructured":"Wurcel V, Scherrer E, Aguiar-Ibanez R, et al. Cost-effectiveness of pembrolizumab for the adjuvant treatment of melanoma patients with lymph node involvement who have undergone complete resection in Argentina. Oncol Ther. 2021;9(1):167\u201385.","journal-title":"Oncol Ther"},{"key":"2484_CR42","unstructured":"National Center for Health Statistics. National Vital Statistics Report. https:\/\/www.cdc.gov\/nchs\/data\/nvsr\/nvsr66\/nvsr66_04.pdf."},{"key":"2484_CR43","unstructured":"National Institute of Statistics and Censuses (INDEC). Abbreviated tables of mortality by sex and age 2008\u20132010. Total for the country and provinces. Demographic Analysis Series No 372013."},{"issue":"19","key":"2484_CR44","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"A Eggermont","year":"2018","unstructured":"Eggermont A, Blank C, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789\u2013801.","journal-title":"N Engl J Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02484-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02484-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02484-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T04:33:27Z","timestamp":1685075607000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02484-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,2]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["2484"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02484-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,2]]},"assertion":[{"value":"12 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}